stopping glp-1 November Blog Meta Monday! WEIGHT REGAIN AFTER

Efficacy and safety of Glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis

Imported peptides bought online are typically unregulated and risky

Supplementary Figure 4 (A) Cumulative data showing relative concentrations of increased and decreased metabolites in R vs HC

"Because only semaglutide is going off-patent, lower prices are expected for semaglutide medications, but not necessarily others"

Although weight loss injectables are not directly associated with DVT, its use in patients with multiple risk factors for clotting disorders, such as obesity or prolonged immobility, may increase that risk unnecessarily